US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study

 
• By Sue Sutter
  
Two arrows pointed in different directions on a signpost 3D illustration
The US FDA holds a different view from Lilly and the EMA on the utility of PFS2. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers